A Phase 1,Open Label, Single Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Dalbavancin in Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment for Bacterial Infections?

Project: Other project

StatusFinished
Effective start/end date11/13/1311/12/15

Funding

  • DUKE UNIVERSITY: $16,635.00